In the future, some Chinese tire companies will pay more than twice the price of the product when they enter the US market. According to the final determination of the US Department of Commerce, Chinese tire manufacturers will be subject to an anti-dumping duty of 14.35% to 87.99% and a countervailing duty of 20.73% to 100.77%.

Recently, it was learned that the two high tariff stacks will cause a heavy blow to the production enterprises, and the products involved in the case may be withdrawn from the US market. In fact, in the first half of the year, Fujian’s tire exports have experienced a serious decline, and the volume and price have fallen. According to industry insiders, local companies need to respond positively after the US “double-reverse” boots are launched.

US “double reverse” affects tire export

"The United States is our main export market, but exports have declined significantly in the first half of this year. According to the current situation, the situation in the second half of the year is even worse," said a person in charge of a tire company. The final result of the US "double-reverse" case against China's tires has a greater impact on the company, and the products involved may have to give up the US market.

A tire manufacturer said that Fujian tire companies, like the national tire industry, will use Europe and the United States as their main export markets. According to this final result, some companies may have to bear more than 100% double tax rate, greatly reducing the price competitiveness in the US market. In fact, since the US Department of Commerce launched an anti-dumping and anti-subsidy investigation on Chinese passenger cars and light truck tires in June 2014, the amount of tires exported from Fujian to the United States has declined.

According to the statistics of Fuzhou Customs, in the first half of this year, Fujian Province exported a total of 17.11 million tires, down 2.3% over the same period of last year; the export value was 1.62 billion yuan, down 9.2% year-on-year; the average export price was 94.9 yuan, down 7% year-on-year. . The province mainly exports to the EU and the United States, of which 6.22 million are exported to the EU, an increase of 5.4%; for the United States, 2.933 million are exported, a decrease of 0.6%.

Experts suggest differential response

People from the Fujian Rubber Industry Association said that in fact, trade friction is not the first time for Chinese tire companies. Especially after the outbreak of the international financial crisis in 2008, domestic tire companies not only suffered from “anti-dumping” investigations, but also under the pressure of “special protection”, namely “transitional guarantee mechanism for specific products” and “special safeguard measures”. It is only expected that the three-year special security case has just arrived, and the "double-reverse" investigation has followed suit. From the current situation, this pressure is difficult to ease in the short term.

However, the association believes that companies involved need not be too discouraged, as long as the product is innovative enough to maintain differentiation from general products, it can also obtain considerable profits.

It is reported that the unit price of tire exports in Fujian Province does not exceed 100 yuan each. At present, all-steel radial tires launched by Fujian enterprises are priced higher than some well-known domestic brands, and the price of exporting abroad is even higher than 60 dollars. Even if it is so expensive, the output value of the existing first-stage production line has exceeded 700 million yuan in a year, and it is zero-inventory sales.

"Like Apple's mobile phone, even though its price is generally higher than that of domestic mobile phones, many users will still buy it." The Fujian Rubber Industry Association pointed out that there is room for innovation in any industry, and there must be no quality. problem.

Rimegepant Intermediates

Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache. While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] are the only members of the "gepants" family of medications remaining in development, and the only CGRP antagonists that possess oral bioavailability. The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular and cardiovascular disease due to their vasoconstrictive properties. Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore safer for use in patients with contraindications to standard therapy.

Rimegepant Intermediates,Rimegepant Cas 1190363-46-2,Rimegepant Cas 1373116-06-3,Rimegepant Cas 1190363-45-1

 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com